Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Remote control-triggering of brain autoimmune disease in the gut.
The neurotrophic hepatocyte growth factor induces protolerogenic human dendritic cells.
Baseline MxA mRNA Expression Predicts Interferon Beta Response in Multiple Sclerosis Patients.
Astroglial PGC-1alpha increases mitochondrial antioxidant capacity and suppresses inflammation: implications for multiple sclerosis.
Role of thalamic diffusion for disease differentiation between multiple sclerosis and ischemic cerebral small vessel disease.
Interaction between the protective effects of cannabidiol and palmitoylethanolamide in experimental model of multiple sclerosis in C57BL/6 mice.
Switching therapies in MS: what are the options?
Epigenetics in autoimmune diseases: Pathogenesis and prospects for therapy.
Varicella-zoster virus encephalomyelitis with a prominent demyelinating component.
Multiple sclerosis: Natalizumab to fingolimod-the washout whitewash.
Fostering adherence to injectable disease-modifying therapies in multiple sclerosis.
Optimal design of clinical trials with biologics using dose-time-response models.
Evolution of diagnostic criteria for multiple sclerosis.
Antibodies as Mediators of Brain Pathology.
White Matter MS-Lesion Segmentation Using a Geometric Brain Model.
Expression of Lymphatic Markers in the Adult Rat Spinal Cord.
Biological markers in cerebrospinal fluid for axonal impairment in multiple sclerosis: acetylcholinesterase activity cannot be considered a useful biomarker.
[Prognostic value of aquaporin-4 antibody in patients of inflammatory demyelinating diseases in central nervous system].
[The effect of tobacco smoking on clinical effectiveness of immunomodulatory treatment in multiple sclerosis patients].
Multiple sclerosis in the Arabian Gulf countries: a consensus statement.
The reliability, precision and clinically meaningful change of walking assessments in multiple sclerosis.
[Characteristics of coping strategies in patients with multiple sclerosis(review)].
Sarcoidosis associated with neuromyelitis optica.
A rare case of Balo concentric sclerosis showing unusual clinical improvement and response with oral prednisolone.
Comprehensive analysis of microRNA profiles in multiple sclerosis including next-generation sequencing.
Pages
« first
‹ previous
…
493
494
495
496
497
498
499
500
501
…
next ›
last »